Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,230.12
(
0.29%
)
US TECH 100
26,942.00
(
0.87%
)
Dow Jones
49,499.27
(
-0.31%
)
Brent Oil
107.80
(
0.00%
)
Bitcoin
78,674.33
(
-0.01%
)
News Focus
News Focus
Post# of 30523
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122926
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: santafe2 post# 28263

Thursday, 06/29/2023 6:30:49 AM

Thursday, June 29, 2023 6:30:49 AM

Post# of 30523
Ozempic and other GLP-1 agonists have manifold safety and tolerability issues including a boxed warning for thyroid cancer. They also cause loss of muscle mass, which is especially worrisome for the elderly.

The triple-agonist (GLP-1, GIP, Glucagon) from LLY that generated oohs and aahs when LLY reported the phase-2 data a few days ago has even worse safety and tolerability issues, including cardiac arrhythmias—see #msg-172233230.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Unleash the power of Level 2

Spot liquidity moves with access to US order books.

Sign Up